DI
IONS icon

DAGCO Inc’s Ionis Pharmaceuticals IONS Stock Holding History

DAGCO Inc’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-80
Closed -$4.05K – 307
2023
Q4 		$4.05K Buy
+80
New +$3.83K ﹤0.01% 229

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAGCO Inc's IONS Position: Q1 2024 in Review

DAGCO Inc sold out of Ionis Pharmaceuticals (IONS) in Q1 2024, closing a stake of 80 shares — an estimated $4.05K sold.

DAGCO Inc first reported a position in IONS in Q4 2023 and held it in 1 quarter. The position peaked at $4.05K in Q4 2023. 361 funds tracked by Wall St. Rank hold IONS as of Q1 2024.

  • DAGCO Inc reported no remaining Ionis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • DAGCO Inc sold 80 Ionis Pharmaceuticals shares in Q1 2024, an estimated $4.05K.
  • DAGCO Inc first reported a position in Ionis Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • DAGCO Inc's Ionis Pharmaceuticals position peaked at $4.05K in Q4 2023.
  • 361 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2024.

Based on DAGCO Inc's 13F filing for Q1 2024, filed 15 May 2024.